Teva Pharmaceutical Industries (FRA:TEV) PEG Ratio: N/A (As of Jul. 12, 2026)


FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
58 GF Score
Price €28.50
GF Value €17.67
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Teva Pharmaceutical Industries's PE Ratio without NRI is 11.33. Teva Pharmaceutical Industries's 5-Year EBITDA growth rate is 0.00%. Therefore, Teva Pharmaceutical Industries's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Teva Pharmaceutical Industries's PEG Ratio or its related term are showing as below:


During the past 13 years, Teva Pharmaceutical Industries's highest PEG Ratio was 14.19. The lowest was 12.00. And the median was 13.27.


FRA:TEV's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.665
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Teva Pharmaceutical Industries  (FRA:TEV) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Teva Pharmaceutical Industries PEG Ratio Related Terms


Teva Pharmaceutical Industries PEG Ratio Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries PEG Ratio Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:TEV vs ZTS, UTHR, VTRS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's PEG Ratio falls into.


FRA:TEV
58GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Teva Pharmaceutical Industries's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=11.332007952286/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €28.50 is trading 61.3% above its estimated GF Value™ of €17.67. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • PEG Ratio: N/A
  • GF Value™: €17.67 vs. price of €28.50 (61.3% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
58GF Score

Get the complete analysis for FRA:TEV

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.50
Price
€17.67
GF Value